Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

Biomarkers in Acute Heart Failure


Biomarkers in Acute Heart Failure: An International, Multi-Center Trial Evaluating the Prognostic and Diagnostic Utility of Biomarkers in Patients With Heart Failure Presenting With Shortness of Breath




Primary Objectives 1. Mid Region pro Adrenomedullin (MR-proADM) is superior to BNP for the prognosis of heart failure (HF) patients and adds incremental value in predicting outcomes for patients presenting to the Emergency Department (ED) with shortness of breath. 2. Mid Region pro A-Type Natriuretic Peptide (MR-proANP) is non-inferior to BNP for the diagnosis of HF in patients presenting to the ED with shortness of breath.

Study Status: Completed


Condition Intervention Phase
Shortness of Breath
Heart Failure
n/a N/A

Verified by Brahms AG July, 2008

Sponsored by: Brahms AG
Information provided by: Brahms AG identifier: NCT00537628

Study Type: Interventional

Study Design: Cohort, Prospective

The Cleveland Clinic
Cleveland, Ohio 44195
United States

Alan S Maisel, MD., Principal Investigator
Stefan D Anker, MD, PhD., Principal Investigator
Frank Peacock, MD., Study Chair

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit
  Information obtained from on
Link to the current record.

Cleveland Clinic Mobile Site